EAST Search History

Ref #	Hits	Search Query	DBs	Default Operator	Plurals	Time Stamp
L2	102	(546/273.7).CCLS.	US-PGPUB	OR	OFF	2007/09/13 10:50
L3	645	(514/341).CCLS.	US-PGPUB	OR	OFF	2007/09/13 10:51

```
=> file caplus
FILE 'CAPLUS' ENTERED AT 09:27:01 ON 13 SEP 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)
```



```
FILE COVERS 1907 - 13 Sep 2007 VOL 147 ISS 12
FILE LAST UPDATED: 12 Sep 2007  (20070912/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply.
They are available for your review at:

http://www.cas.org/infopolicy.html

=> d que
L3             1 SEA FILE=REGISTRY 847951-87-5
L4             1 SEA FILE=CAPLUS L3


=> d l4 ibib abs hitstr

L4   ANSWER 1 OF 1  CAPLUS  COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER:         2005:238978  CAPLUS
DOCUMENT NUMBER:          142:303555
TITLE:                    Adamantanammonium salts of omeprazole and esomeprazole
INVENTOR(S):              Dahlstroem, Mikael; Braendstroem, Arne
PATENT ASSIGNEE(S):       Astrazeneca AB, Swed.
SOURCE:                   PCT Int. Appl., 25 pp.
                          CODEN: PIXXD2
DOCUMENT TYPE:            Patent
LANGUAGE:                 English
FAMILY ACC. NUM. COUNT:   1
PATENT INFORMATION:

     PATENT NO.           KIND   DATE        APPLICATION NO.          DATE
     ---------------      ----   --------    --------------------     --------
     WO 2005023796         A1    20050317    WO 2004-SE1258           20040901
     WO 2005023796         A8    20060406
         W:  AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,
             CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,
             GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
             LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI,
             NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY,
             TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
         RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM,
             AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK,
             EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE,
             SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE,
             SN, TD, TG
     CA 2549465            A1    20050317    CA 2004-2549465          20040901
     EP 1664019            A1    20060607    EP 2004-775364           20040901
         R:  AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
```

IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK

JP 2007504222	T	20070301	JP 2006-525304	20040901
US 2007004778	A1	20070104	US 2006-569819	20060227
PRIORITY APPLN. INFO.:			SE 2003-2381 A	20030904
			WO 2004-SE1258 W	20040901

AB The present invention relates to new salts of omeprazole and esomeprazole resp., i.e. salts of 5-methoxy-2-[[(4-methoxy-3,5-dimethyl-2-pyridinyl)-methyl]sulfinyl]-1H-benzimidazole and the (S)-enantiomer thereof. More specifically, the present invention relates to adamantanammonium salt of the compds., formed by a reaction of omeprazole and esomeprazole resp. and adamantanamine. The present invention also relates to a process for preparing the compds. of the invention, a pharmaceutical preparation and a method for treatment of gastric related disorders by administering the compds. of the invention.

IT 847951-87-5P
RL: PRP (Properties); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(adamantanammonium salts of omeprazole and esomerazole)

RN 847951-87-5 CAPLUS

CN Tricyclo[3.3.1.13,7]decan-1-amine, compd. with 5-methoxy-2-[(S)-[(4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]sulfinyl]-1H-benzimidazole (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 119141-88-7
CMF C17 H19 N3 O3 S

Absolute stereochemistry. Rotation (-).



CM 2

CRN 768-94-5
CMF C10 H17 N



REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=>

```
=> file caplus
FILE 'CAPLUS' ENTERED AT 09:11:15 ON 13 SEP 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)
```



```
FILE COVERS 1907 - 13 Sep 2007  VOL 147 ISS 12
FILE LAST UPDATED: 12 Sep 2007  (20070912/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply.
They are available for your review at:

http://www.cas.org/infopolicy.html

=> d que
L1          560 SEA FILE=CAPLUS ADMANTAN AND (OMEPRAZOLE) OR (ESOMEPRAZOLE)
L2           12 SEA FILE=CAPLUS L1 AND AMMONIUM


=> d l2 1-12 ibib abs hitstr

L2   ANSWER 1 OF 12  CAPLUS  COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER:         2007:193474  CAPLUS
DOCUMENT NUMBER:          146:236149
TITLE:                    Process for the preparation of amorphous form of
                          neutral esomeprazole
INVENTOR(S):              Kumar, Bobba Venkata Siva; Kulkarni, Pravin
                          Bhalchandra; Suryawanshi, Anil Ganpat; Raut, Changdev
                          Namdev; Pradhan, Nitin Sharad Chandra
PATENT ASSIGNEE(S):       Glenmark Pharmaceuticals Limited, India
SOURCE:                   U.S. Pat. Appl. Publ., 8pp.
                          CODEN: USXXCO
DOCUMENT TYPE:            Patent
LANGUAGE:                 English
FAMILY ACC. NUM. COUNT:   1
PATENT INFORMATION:

     PATENT NO.           KIND   DATE        APPLICATION NO.          DATE
     ---------------      ----   --------    --------------------     --------
     US 2007043085         A1    20070222    US 2006-507284           20060821
     IN 2005MU00979        A     20070629    IN 2005-MU979            20050819
PRIORITY APPLN. INFO.:                       IN 2005-MU979        A   20050819
AB   A process for preparing neutral esomeprazole in an amorphous form
     is provided comprising (a) providing an aqueous solution comprising a salt of
     esomeprazole; (b) neutralizing the solution with a neutralization
     agent to provide a neutralized solution; (c) contacting the neutralized
solution
     with an extracting solvent; and (d) recovering the neutral esomeprazole
     in an amorphous form.

L2   ANSWER 2 OF 12  CAPLUS  COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER:         2007:193042  CAPLUS
```

DOCUMENT NUMBER: 146:258967
TITLE: Drug-surfactant complex for sustained release
INVENTOR(S): Kim, Cherng-Ju
PATENT ASSIGNEE(S): The Board of Trustees of the University of Arkansas, USA
SOURCE: PCT Int. Appl., 45pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2007022356	A2	20070222	WO 2006-US32147	20060817
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
US 2007042041	A1	20070222	US 2005-207126	20050817
PRIORITY APPLN. INFO.:			US 2005-207126 A	20050817

OTHER SOURCE(S): MARPAT 146:258967

AB The invention involves sustained-release pharmaceutical compns. containing a water-soluble ionic small mol. pharmaceutical agent complexed with an oppositely charged surfactant, particularly a natural bile surfactant. The complexes are sustained-release ionic complexes. The complexes release the ionic pharmaceutical agents into aqueous solution slowly and with zero-order kinetics. Thus, they can be formulated into sustained-release pharmaceutical compns. The invention also provides sustained- release pharmaceutical compns. containing a water-soluble ionic small mol. pharmaceutical agent complexed with an oppositely charged non-surfactant amphipathic substance, particularly benzathine or pamoate. For example, diltiazem-hydrochloride and sodium deoxycholate were sep. dissolved in water and then solns. were mixed. A precipitate of diltiazem-deoxycholate complex was formed. The precipitate was removed and formulated into tablet.

L2 ANSWER 3 OF 12 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2007:175448 CAPLUS
DOCUMENT NUMBER: 146:251847
TITLE: Process for the preparation of substituted 2-(2-pyridylmethyl)sulfinyl-1H-benzimidazole compounds
INVENTOR(S): Ludescher, Johannes; Khan, Rashid Abdul Rehman; Das, Tonmoy Chitta
PATENT ASSIGNEE(S): Sandoz AG, Switz.
SOURCE: PCT Int. Appl., 19pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2007017244	A2	20070215	WO 2006-EP7832	20060808

WO 2007017244 A3 20070426
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA
PRIORITY APPLN. INFO.: SI 2005-228 A 20050810
OTHER SOURCE(S): CASREACT 146:251847; MARPAT 146:251847
GI



I

AB A process for the preparation of substituted 2-(2-pyridylmethyl) sulfinyl-1H-benzimidazoles compds. I [R1 = H, MeO or CHF2O; R3 = Me or MeO; R3 = 3-methoxypropoxy, MeO or 2,2,2-trifluoroethoxy; R4 = H or Me] from a suitable solvent or a mixture of solvents in the presence of a quaternary ammonium compound For example, coupling reaction of 2-chloromethyl-3-methyl-4-(2,2,2-trifluoroethoxy)pyridine•HCl with 2-mercaptobenzimidazole, and followed by oxidation by m-CPBA, gave crude lansoprazole. After purification in xylene/ethanol and in the presence of tetra(n-butyl)ammonium hydroxide, pure lansoprazole was provided. The pharmaceutical compns. of I were claimed.

L2 ANSWER 4 OF 12 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2006:1156275 CAPLUS
DOCUMENT NUMBER: 145:460579
TITLE: Pharmaceutical compositions comprising substituted benzimidazole as proton pump inhibitors and buffers and vitamin B12 and ferrous salts
INVENTOR(S): Phillips, Jeffrey
PATENT ASSIGNEE(S): The Curators of the University of Missouri, USA
SOURCE: PCT Int. Appl., 35pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006116582	A2	20061102	WO 2006-US15982	20060425
WO 2006116582	A3	20070726		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC,

VN, YU, ZA, ZM, ZW
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA
PRIORITY APPLN. INFO.: US 2005-675133P P 20050426
OTHER SOURCE(S): MARPAT 145:460579
AB The present invention relates to, inter alia, pharmaceutical compns. comprising one or more of an acid labile proton pump inhibitor, a buffering agent, and vitamin B12; to methods for manufacture of such compns., and to use of such compns. in treating and preventing diseases and/or disorders. For example, tablets contained omeprazole, vitamin B12, ferrous sulfate, sodium bicarbonate, calcium carbonate, sodium carbonate and magnesium hydroxide.

L2 ANSWER 5 OF 12 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2006:982400 CAPLUS
DOCUMENT NUMBER: 145:342507
TITLE: Stable tablet dosage forms of proton pump inhibitors
INVENTOR(S): Namburi, Ranga R.; Karri, Rama Prasad; Tallapragada, Ravi Srikanth; Palkhiwala, Burgise F.
PATENT ASSIGNEE(S): Qpharma, LLC, USA
SOURCE: U.S. Pat. Appl. Publ., 12pp.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2006210637	A1	20060921	US 2005-82610	20050317
WO 2006101794	A2	20060928	WO 2006-US8855	20060314
WO 2006101794	A3	20070104		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

PRIORITY APPLN. INFO.: US 2005-82610 A 20050317
AB This invention relates to a method of making oral formulations of practically water insol., or very slightly water soluble proton pump inhibitors, the oral dosage forms so made, and methods of use thereof. The oral dosage form has a core tablet of compressed particles composed of powder particles of a pharmaceutically acceptable material, having coated thereon admixt. of an amorphous, salt form of a benzimidazole proton pump inhibitor produced in-situ; and a pharmaceutically acceptable, water-soluble, hydrophilic polymer having a surfactant functionality. The coated core tablet has a pharmaceutically acceptable sub-coating on the core tablet; and a pharmaceutically acceptable enteric coating on the sub-coating. The coated tablet may provide enhanced absorption when administered orally. A core tablet containing omeprazole 20.0 mg was coated with Opadry 03K19299 5.517, and disodium hydrogen phosphate 0.184 to obtain a delayed-release tablet.

L2 ANSWER 6 OF 12 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2006:86075 CAPLUS
DOCUMENT NUMBER: 144:163447
TITLE: Sensitive quantification of omeprazole and its metabolites in human plasma by liquid chromatography-mass spectrometry
AUTHOR(S): Hofmann, Ute; Schwab, Matthias; Treiber, Gerd; Klotz, Ulrich
CORPORATE SOURCE: Dr. Margarete Fischer-Bosch-Institute of Clinical Pharmacology, Stuttgart, D-70376, Germany
SOURCE: Journal of Chromatography, B: Analytical Technologies in the Biomedical and Life Sciences (2006), 831(1-2), 85-90
CODEN: JCBAAI; ISSN: 1570-0232
PUBLISHER: Elsevier B.V.
DOCUMENT TYPE: Journal
LANGUAGE: English
AB A sensitive method was developed for the simultaneous determination of omeprazole and its major metabolites 5-hydroxyomeprazole and omeprazole sulfone in human plasma by HPLC-electrospray mass spectrometry. Following liquid-liquid extraction HPLC separation was achieved on a ProntoSil AQ, C18 column using a gradient with 10 mM ammonium acetate in water (pH 7.25) and acetonitrile. The mass spectrometer was operated in the selected ion monitoring mode using the resp. MH+ ions, m/z 346 for omeprazole, m/z 362 for 5-hydroxy-omeprazole and omeprazole-sulfone and m/z 300 for the internal standard (2-{[(3,5-dimethylpyridine-2-yl)methyl]thio}-1H-benzimidazole-5-yl)methanol. The limit of quantification (LOQ) achieved with this method was 5 ng/mL for 5-hydroxyomeprazole and 10 ng/mL for omeprazole and omeprazole-sulfone using 0.25 mL of plasma. Intra- and interassay variability was below 11% over the whole concentration range from 5 to 250 ng/mL for 5-hydroxyomeprazole and from 10 to 750 ng/mL for omeprazole and omeprazole-sulfone. The method was successfully applied to the determination of pharmacokinetic parameters of esomeprazole and the two major metabolites after a single dose and under steady state conditions.
REFERENCE COUNT: 13 THERE ARE 13 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L2 ANSWER 7 OF 12 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2005:1292139 CAPLUS
DOCUMENT NUMBER: 144:36340
TITLE: A novel stereoselective synthesis of benzimidazole sulfoxides
INVENTOR(S): Parthasaradhi Reddy, Bandi; Rathnakar Reddy, Kura; Raji Reddy, Rapolu; Muralidhara Reddy, Dasari
PATENT ASSIGNEE(S): Hetero Drugs Limited, India
SOURCE: PCT Int. Appl., 41 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005116011	A1	20051208	WO 2004-IN143	20040528

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY,

TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

EP 1748998	A1	20070207	EP 2004-735319	20040528
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LI, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR				
US 2006166986	A1	20060727	US 2004-503846	20040806
PRIORITY APPLN. INFO.:			WO 2004-IN143 W	20040528

OTHER SOURCE(S): CASREACT 144:36340; MARPAT 144:36340
GI



I



II

AB The present invention relates to a process for stereoselective synthesis of substituted sulfoxides of formula I [R = (un)substituted 2-pyridinyl; X = -CH(R5)- or (un)disubstituted-ortho-phenyl; R1,R2,R3,R4 = independently H, alkyl;, alkoxy, halogen, etc.; R5 = H or forms an alkylene chain together with R] either as a single enantiomer or in an enantiomerically enriched form. Thus, 5-methoxy-2-[[(4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]thio]-1H-benzimidazole is reacted with (R)-camphorsulfonyl chloride to form a mixture of 1-(R)-camphorsulfonyl-5-(and 6-)methoxy-2-[(3,5-dimethyl-4-methoxy-2-pyridyl)methylthio]-1H-benzimidazole, oxidized to obtain a diastereomeric excess of 1-(R)-camphorsulfonyl-(5- and 6-)-methoxy-2-[(3,5-dimethyl-4-methoxy-2-pyridyl)methyl-(S)-sulfinyl]-1H-benzimidazole over 1-(R)-camphorsulfonyl-(5- and 6-)-methoxy-2-[(3,5-dimethyl-4-methoxy-2-pyridyl)methyl-(R)-sulfinyl]-1H-benzimidazole. The diastereomers are separated by fractional crystallization and the separated 1-(R)-camphorsulfonyl-(5- and 6-)-methoxy-2-[(3,5-dimethyl-4-methoxy-2-pyridyl)methyl-(S)-sulfinyl]-1H-benzimidazole is deprotected to give (S)-esomeprazole (II).

REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L2 ANSWER 8 OF 12 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2005:1193121 CAPLUS
DOCUMENT NUMBER: 143:460147
TITLE: process for preparing pyridinylmethyl benzimidazolyl

sulfoxides in enantiomerically enriched form or as single enantiomers via separation of diastereomers

INVENTOR(S): Parthasaradhi Reddy, Bandi; Rathnakar Reddy, Kura; Raji Reddy, Rapolu; Muralidhara Reddy, Dasari

PATENT ASSIGNEE(S): Hetero Drugs Limited, India

SOURCE: PCT Int. Appl., 30 pp.
CODEN: PIXXD2

DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005105786	A1	20051110	WO 2004-IN118	20040428
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
EP 1740571	A1	20070110	EP 2004-729974	20040428
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LI, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR				
US 2006089386	A1	20060427	US 2004-503830	20040806
US 7176319	B2	20070213		
US 2007129405	A1	20070607	US 2007-620830	20070108
US 2007129406	A1	20070607	US 2007-620843	20070108

PRIORITY APPLN. INFO.: WO 2004-IN118 W 20040428
US 2004-503830 A3 20040806

OTHER SOURCE(S): CASREACT 143:460147; MARPAT 143:460147

GI



I



II







AB Single enantiomers or enantiomerically enriched mixts. of title compds. [I; R = Q1, Q2; X = CHR8, Q3; R1-R4 = H, alkyl, alkoxy, halo, haloalkoxy, alkylcarbonyl, alkoxycarbonyl, oxazolyl, CF3; adjacent R1-R4 form (substituted) ring structures; R5, R7 = H, alkyl, alkylthio, alkoxy, fluoroalkoxy, alkoxyalkoxy, dialkylamino, piperidino, morpholino,

phenylalkyl, phenylalkoxy; R6 = R5, NO2; R8 = H; R7R8 = alkylene; R9, R10 = H, halo, alkyl], were prepared by reaction of racemic I with substantially enantiomerically pure R11ZY (R11 = chiral moiety with ≥1 asym. center; Z = SO2, SO, CO; Y = leaving group) to give diastereomers (II; variables as above) followed by separation of diastereomers and deprotection with acid or base followed by optional conversion to salts. Thus, racemic omeprazole reacted with (S)-camphorsulfonyl chloride to form a diastereomeric mixture and the diastereomers were separated by fractional crystallization from isopropanol, followed by cleavage with NaOH in MeOH/H2O to give esomeprazole.

REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L2 ANSWER 9 OF 12 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2005:983611 CAPLUS
DOCUMENT NUMBER: 143:292527
TITLE: Bioavailability and improved delivery of alkaline pharmaceutical drugs
INVENTOR(S): Yu, Ruey J.; Van Scott, Eugene J.
PATENT ASSIGNEE(S): USA
SOURCE: U.S. Pat. Appl. Publ., 16 pp., Cont.-in-part of U.S. Ser. No. 792,273.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2005196418	A1	20050908	US 2005-50434	20050204
US 2004214215	A1	20041028	US 2004-792273	20040304
WO 2006084174	A2	20060810	WO 2006-US3917	20060206

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

PRIORITY APPLN. INFO.:

US 2004-792273	A2	20040304
US 2003-452557P	P	20030307
US 2005-50434	A	20050204

OTHER SOURCE(S): MARPAT 143:292527

AB Embodiments of the invention relate to a composition, a process of making the composition, and to the use of the composition The compns. include a mol. complex formed between an alkaline pharmaceutical drug and at least one selected from a hydroxy acid, a polyhydroxy acid, a related acid, a lactone, or combinations thereof. The compns. provide improved bioavailability and improved delivery of the drug into the cutaneous tissues. For example, diphenhydramine hydrochloride 29 g (0.1 mol) was dissolved in water and 5 N sodium hydroxide generating diphenhydramine free base. Gluconolactone 18 g (0.1 mol) was added to form a mol. complex of 0.1 mol diphenhydramine free base with 0.1 mol gluconic acid/gluconolactone. The solution thus obtained was used for various forms of topical formulations including oil-in-water creams, lotions, gels and solns.

L2 ANSWER 10 OF 12 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2005:523236 CAPLUS
DOCUMENT NUMBER: 143:48119
TITLE: Reverse micelle formulations comprising one or more surfactant, a hydrophilic phase and lipophilic or hydrophobic compounds
INVENTOR(S): Liang, Likan
PATENT ASSIGNEE(S): Shire Laboratories, Inc., USA
SOURCE: PCT Int. Appl., 38 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005053612	A2	20050616	WO 2004-US39567	20041124
WO 2005053612	A3	20050915		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2537029	A1	20050616	CA 2004-2537029	20041124
US 2005191343	A1	20050901	US 2004-995942	20041124
EP 1706098	A2	20061004	EP 2004-812147	20041124
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK, IS				
JP 2007512373	T	20070517	JP 2006-541711	20041124

PRIORITY APPLN. INFO.:

US 2003-525572P	P	20031126
US 2004-541389P	P	20040202
US 2004-566157P	P	20040428
WO 2004-US39567	W	20041124

AB The present invention is directed to reverse micellar formulations for the delivery of hydrophobic or lipophilic compds., particularly therapeutic compds. The formulations contains one or more non-ionic surfactants or a mixture of nonionic and ionic surfactants, a hydrophilic phase composed of one or more hydrophilic solvents and/or solubilizers and/ or aqueous media, and one or more therapeutically active, hydrophobic agents. The compns. optionally further contain P-glycoprotein inhibitors, absorption enhancers or promoters, tight junction modulators, lipid membrane mobilizers, and antioxidants. For example, fenofibrate reverse micelle systems containing both hydrophilic and surfactant-miscible solubilizers were prepared containing PEG-8-caprylic/capric glycerides 6 g, PEG-4 lauryl ether 3.7 g, PEG 400 0.15 g, water 0.15 g and fenofibrate 1 g.

L2 ANSWER 11 OF 12 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2005:238979 CAPLUS
DOCUMENT NUMBER: 142:303556
TITLE: Cyclohexylethylammonium salts of omeprazole and esomeprazole
INVENTOR(S): Dahlstroem, Mikael; Lindqvist, Bo
PATENT ASSIGNEE(S): Astrazeneca AB, Swed.
SOURCE: PCT Int. Appl., 20 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent

LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005023797	A1	20050317	WO 2004-SE1259	20040901
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2535983	A1	20050317	CA 2004-2535983	20040901
EP 1664020	A1	20060607	EP 2004-775365	20040901
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK				
JP 2007504223	T	20070301	JP 2006-525305	20040901
US 2007021467	A1	20070125	US 2006-569820	20060227
PRIORITY APPLN. INFO.:			SE 2003-2382 A	20030904
			WO 2004-SE1259 W	20040901

AB The present invention relates to new salts of the single enantiomers of omeprazole, i.e. salts of (S)-5-methoxy-2-[[(4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]sulfinyl]-1H-benzimidazole ((S)-omeprazole) and (R)-omeprazole resp. More specifically, the present invention relates to 1-cyclohexylethyl ammonium salts of the compds., formed by a reaction of (S)-omeprazole and (R)-omeprazole resp. and 1-cyclohexylethylamine. The present invention also relates to a process for preparing the compds. of the invention, a pharmaceutical preparation and a method for treatment of gastric related disorders by administering the compds. of the invention.

REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L2 ANSWER 12 OF 12 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2003:511859 CAPLUS
DOCUMENT NUMBER: 139:90459
TITLE: Use of an immediate-release powder in pharmaceutical and nutraceutical compositions
INVENTOR(S): Besse, Jerome; Besse, Laurence
PATENT ASSIGNEE(S): Fr.
SOURCE: U.S. Pat. Appl. Publ., 5 pp.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2003124191	A1	20030703	US 2002-106923	20020325
FR 2834212	A1	20030704	FR 2001-16934	20011227
FR 2834212	B1	20040709		
CA 2471903	A1	20030710	CA 2002-2471903	20021227
WO 2003055464	A1	20030710	WO 2002-FR4575	20021227
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,				

LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH,
PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ,
UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES,
FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ,
CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

AU 2002364489	A1	20030715	AU 2002-364489	20021227
EP 1458356	A1	20040922	EP 2002-799854	20021227
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK				
BR 2002015380	A	20041207	BR 2002-15380	20021227
US 2005118272	A1	20050602	US 2003-500213	20021227
JP 2005520799	T	20050714	JP 2003-556042	20021227
HU 200500509	A2	20050928	HU 2005-509	20021227
RU 2302232	C2	20070710	RU 2004-122919	20021227
MX 2004PA06181	A	20050419	MX 2004-PA6181	20040622
NO 2004003172	A	20040914	NO 2004-3172	20040726
PRIORITY APPLN. INFO.:			FR 2001-16934 A	20011227
			WO 2002-FR4575 W	20021227

AB The present invention relates to the use of a powder comprising at least one active substance, at least one surfactant, at least one wetting agent and at least one diluent, for preparing a pharmaceutical or nutraceutical composition, this composition allowing rapid and immediate release of the active substance. Granules containing phloroglucinol 10, sorbitol 89, and propylene glycol 1% were prepared

=>